These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

898 related items for PubMed ID: 24429127

  • 1. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
    Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Sanford L, Lettis S, Crim C, Calverley PM.
    Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
    [Abstract] [Full Text] [Related]

  • 2. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [Abstract] [Full Text] [Related]

  • 3. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.
    Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID.
    Lancet Respir Med; 2015 Jun; 3(6):435-42. PubMed ID: 25878028
    [Abstract] [Full Text] [Related]

  • 4. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
    Siler TM, Nagai A, Scott-Wilson CA, Midwinter DA, Crim C.
    Respir Med; 2017 Feb; 123():8-17. PubMed ID: 28137501
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice.
    Vestbo J, Leather D, Diar Bakerly N, New J, Gibson JM, McCorkindale S, Collier S, Crawford J, Frith L, Harvey C, Svedsater H, Woodcock A, Salford Lung Study Investigators.
    N Engl J Med; 2016 Sep 29; 375(13):1253-60. PubMed ID: 27593504
    [Abstract] [Full Text] [Related]

  • 6. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.
    Martinez FJ, Boscia J, Feldman G, Scott-Wilson C, Kilbride S, Fabbri L, Crim C, Calverley PM.
    Respir Med; 2013 Apr 29; 107(4):550-9. PubMed ID: 23332861
    [Abstract] [Full Text] [Related]

  • 7. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD.
    Crim C, Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Lettis S, Calverley PM.
    Ann Am Thorac Soc; 2015 Jan 29; 12(1):27-34. PubMed ID: 25490706
    [Abstract] [Full Text] [Related]

  • 8. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.
    Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, Martinez F, Yates J, Newby DE, SUMMIT Investigators.
    Lancet; 2016 Apr 30; 387(10030):1817-26. PubMed ID: 27203508
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
    Dransfield MT, Feldman G, Korenblat P, LaForce CF, Locantore N, Pistolesi M, Watkins ML, Crim C, Martinez FJ.
    Respir Med; 2014 Aug 30; 108(8):1171-9. PubMed ID: 24998880
    [Abstract] [Full Text] [Related]

  • 10. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.
    Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, Singh D, Tabberer M, Wise RA, Pascoe SJ, IMPACT Investigators.
    N Engl J Med; 2018 May 03; 378(18):1671-1680. PubMed ID: 29668352
    [Abstract] [Full Text] [Related]

  • 11. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
    Kerwin EM, Scott-Wilson C, Sanford L, Rennard S, Agusti A, Barnes N, Crim C.
    Respir Med; 2013 Apr 03; 107(4):560-9. PubMed ID: 23352226
    [Abstract] [Full Text] [Related]

  • 12. A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD.
    Bhatt SP, Dransfield MT, Cockcroft JR, Wang-Jairaj J, Midwinter DA, Rubin DB, Scott-Wilson CA, Crim C.
    Int J Chron Obstruct Pulmon Dis; 2017 Apr 03; 12():351-365. PubMed ID: 28176907
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
    Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, Tabberer M, Harris S, Church A.
    Lancet Respir Med; 2014 Jun 03; 2(6):472-86. PubMed ID: 24835833
    [Abstract] [Full Text] [Related]

  • 14. Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease.
    Bollmeier SG, Prosser TR.
    Ann Pharmacother; 2014 Feb 03; 48(2):250-7. PubMed ID: 24259654
    [Abstract] [Full Text] [Related]

  • 15. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD.
    Agustí A, de Teresa L, De Backer W, Zvarich MT, Locantore N, Barnes N, Bourbeau J, Crim C.
    Eur Respir J; 2014 Mar 03; 43(3):763-72. PubMed ID: 24114969
    [Abstract] [Full Text] [Related]

  • 16. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
    Bremner PR, Birk R, Brealey N, Ismaila AS, Zhu CQ, Lipson DA.
    Respir Res; 2018 Jan 25; 19(1):19. PubMed ID: 29370819
    [Abstract] [Full Text] [Related]

  • 17. Fluticasone furoate/vilanterol: a review of its use in chronic obstructive pulmonary disease.
    McKeage K.
    Drugs; 2014 Sep 25; 74(13):1509-22. PubMed ID: 25074268
    [Abstract] [Full Text] [Related]

  • 18. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.
    Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Hartley B, Lange P, Lettis S, Lipson DA, Lomas DA, Martinez FJ, Papi A, Roche N, van der Valk RJP, Wise R, Singh D.
    Lancet Respir Med; 2019 Sep 25; 7(9):745-756. PubMed ID: 31281061
    [Abstract] [Full Text] [Related]

  • 19. Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial.
    Hanania NA, Mannino DM, Criner GJ, Dransfield MT, Han MK, Jones CE, Kilbride S, Lomas DA, Martin N, Martinez FJ, Singh D, Wise RA, Halpin DMG, Lima R, Lipson DA.
    Chest; 2021 Mar 25; 159(3):985-995. PubMed ID: 33031829
    [Abstract] [Full Text] [Related]

  • 20. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
    Stynes G, Svedsater H, Wex J, Lettis S, Leather D, Castelnuovo E, Detry M, Berry S.
    Respir Res; 2015 Feb 15; 16(1):25. PubMed ID: 25849223
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.